According to a study by Chevalier and colleagues, a single intra-articular injection of anakinra is no more effective than placebo for treating the symptoms of knee osteoarthritis (OA).

While the first successful biologic agents targeted tumor necrosis factor (TNF), followed by interleukin-1 inhibition with anakinra, B-cell depletion with rituximab and co-stimulation inhibition ...